ERBB2 and neoplasm: Use of dual HER2 blockade with induction chemotherapy followed by maintenance HER2-targeted treatment may enhance clinical benefit overall, by first maximizing tumor reduction with a fixed number of cycles of initial chemotherapy in combination with dual HER2 blockade, then switching to maintenance HER2-targeted therapy alone for better long-term tolerability [11–13, 15, 16].